420 related articles for article (PubMed ID: 17559722)
1. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
[TBL] [Abstract][Full Text] [Related]
2. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
5. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
Correale J; Cristiano E
Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
[TBL] [Abstract][Full Text] [Related]
6. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
Bayas A; Gold R
J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
[TBL] [Abstract][Full Text] [Related]
7. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
8. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
Girouard N; Théorêt G
Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
10. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
Lundy J; Craig BM
Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
[TBL] [Abstract][Full Text] [Related]
11. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.
Cunningham A; Gottberg K; von Koch L; Hillert J
Acta Neurol Scand; 2010 Mar; 121(3):154-60. PubMed ID: 20055771
[TBL] [Abstract][Full Text] [Related]
12. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
Ouallet JC
Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L
Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794
[TBL] [Abstract][Full Text] [Related]
14. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
17. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
18. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z
Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]